Sep 4, 2026 05:05PM
Aug 14, 2026 05:02PM
Jun 3, 2026 08:02AM
Jun 3, 2026 08:00AM
Jun 3, 2026 07:25AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Jun 1, 2026 07:01AM
Jun 1, 2026 07:00AM
May 29, 2026 05:31PM
May 29, 2026 05:30PM
May 6, 2026 08:00AM
Apr 22, 2026 07:01AM
Apr 22, 2026 07:01AM Actinium presents data on Actimab-A mechanism at cancer research meeting
Apr 22, 2026 07:00AM
Apr 22, 2026 07:00AM
Apr 6, 2026 07:30AM
Apr 6, 2026 07:30AM
Feb 17, 2026 07:42AM
Dec 12, 2025 08:45AM
Dec 12, 2025 08:45AM Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,
Dec 1, 2025 08:45AM
Dec 1, 2025 08:45AM
Nov 4, 2025 07:30AM
Nov 3, 2025 08:30AM
Oct 27, 2025 07:00AM
Oct 27, 2025 07:00AM
Oct 24, 2025 08:30AM Actinium presents ATNM-400 data showing efficacy in prostate cancer models
Oct 24, 2025 08:30AM
Oct 13, 2025 12:10PM
Oct 13, 2025 08:30AM
Jul 31, 2025 08:31AM
Jul 31, 2025 08:30AM
Jun 23, 2025 11:31AM
Jun 23, 2025 11:30AM Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled
May 26, 2025 10:20AM
May 25, 2025 09:03AM
May 24, 2025 08:50AM
May 22, 2025 04:00PM
May 22, 2025 09:00AM
May 21, 2025 09:53AM
May 19, 2025 06:40PM SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 18, 2025 10:00AM
May 17, 2025 08:03AM
May 16, 2025 04:00PM
May 15, 2025 10:20AM
May 13, 2025 09:00AM
May 12, 2025 05:48PM
May 11, 2025 04:00PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 10, 2025 08:04AM

330,672 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All